MedPath

Clinical study on Turmeric mouth wash in the treatment of Oral ulcers due to cancer therapy.

Phase 2
Completed
Conditions
Subjects with head and neck cancer scheduled to receive chemotherapy or radiotherapy as standard care and with history or prone to develop oral mucositis during cancer chemotherapy or radiotherapy
Registration Number
CTRI/2018/03/012371
Lead Sponsor
The Himalaya Drug Company
Brief Summary

The study is an  open label comparative three-arm randomized parallel clinical study in which 2 variants of Turmeric Oral Rinse will be compared with normal saline for the efficacy and safety in patients during cancer chemotherapy and radiotherapy. Forty five ssubjects who fulfil the inclusion criteria will be selected. They will be randomised to one of the three groups namely Turmeric oral rinse variant 1 (Turmeric oral rinse with xanthine gum), Turmeric oral rinse Variant 2 (Turmeric oral rinse without xanthine gum) and Normal saline of 15 cases each. The subjects will be advised to use 10 ml of oral rinse to rinse/swish the mouth for 1 minute four times a day. The subjects will be instructed to attend for follow up at the end of every week for 6 weeks. The study was conducted at single centre in India.

The primary outcome measures were Clinical assessments of Mucositis as per the World Health Organisation grading.

Outcome measures were measured at entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
45
Inclusion Criteria
  • 1 Subjects with confirmed histopathologically with head and neck cancer (according to TNM classification) preferably oropharyngeal scheduled to receive chemotherapy or radiotherapy as a standard care.
  • 2 Subjects with history or prone to develop oral mucositis during cancer chemotherapy or radiotherapy.
  • 3 Subjects aged >18 years of either the sex.
  • 4 Subjects willing to give a written informed consent and follow the schedule of the study as per the protocol.
Exclusion Criteria
  • 1 Has participated in a similar clinical investigation in the past four weeks.
  • 2 Severe uncontrolled systemic disorders, diabetes, Hypertension, or genetic and endocrinal disorders.
  • 3 Has used a similar product in the past four weeks.
  • 4 Subjects who refused to sign informed consent.
  • 5 Pregnant and lactating women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical assessment of Mucositis as per the World Health Organisation gradingAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Secondary Outcome Measures
NameTimeMethod
Difficulty in drinkingAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Location of ulcersAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Number of ulcersAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Burning sensationAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Difficulty in chewingAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek
Difficulty in opening the mouthAt entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5thweek and end of 6thweek

Trial Locations

Locations (1)

M S Ramaiah Medical College and Hospital

🇮🇳

Bangalore, KARNATAKA, India

M S Ramaiah Medical College and Hospital
🇮🇳Bangalore, KARNATAKA, India
Dr Kirthi Koushik
Principal investigator
09901845412
kirthi.koushik@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.